Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases

Abstract

This retrospective single-centre study suggests that the introduction of lapatinib improved survival in patients with BM from HER2-positive breast cancer. Patients with KPS ≥70 may benefit when treated with lapatinib in addition to trastuzumab after completion of local therapy.